LG 30435, a new potential antiasthmatic agent.
LG 30435 is a new quarternary phenothiazine derivative with H1-antihistaminic and antimuscarinic properties. The ability of LG 30435 to prevent changes in respiratory mechanics, induced by different mediators and the immunological reaction, was monitored together with biological and radioimmunological determination of circulating thromboxane-A2 (TxA2) in anaesthetized guinea-pigs. LG 30435 dose-dependently reduces the bronchoconstriction and TxA2 generation caused by different stimuli such as histamine, acetylcholine, leukotriene C4 (LTC4) and PAF-acether. In addition i.v. and aerosol administration of LG 30435 causes a dose-dependent reduction of the increase in airway resistance and TxA2 generation induced by ovalbumin challenge in actively sensitized animals. LG 30435 infused at different concentrations through the isolated guinea-pig lungs inhibits the TxB2 generation caused by different anaphylactic mediators, but not by arachidonic acid. These data, which further substantiate the bronchodilator activity of LG 30435 against a variety of stimuli and demonstrate its protective properties on lung anaphylaxis, suggest that this compound has a potential therapeutic value in the treatment of asthma.
Berti
F
F
Institute of Pharmacological Sciences, University of Milan, Italy.
Daffonchio
L
L
Magni
F
F
Omini
C
C
Rossoni
G
G
Subissi
A
A
D000707:Anaphylaxis / Q000188:drug therapy; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D008297:Male; D010640:Phenothiazines / Q000494:pharmacology*; D015656:Respiratory Mechanics / Q000187:drug effects*; D013928:Thromboxane A2 / Q000378:metabolism
D001993:Bronchodilator Agents; D010640:Phenothiazines; C049967:LG 30435; D013928:Thromboxane A2